- Home
- THRY vs BEATW Comparison
THRY vs BEATW Comparison
Compare THRY & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRY
- BEATW
- Stock Information
- Founded
- THRY 2012
- BEATW 2015
- Country
- THRY United States
- BEATW United States
- Employees
- THRY N/A
- BEATW 21
- Industry
- THRY Industrial Machinery/Components
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- THRY Industrials
- BEATW Technology
- Exchange
- THRY Nasdaq
- BEATW Nasdaq
- Market Cap
- THRY N/A
- BEATW N/A
- IPO Year
- THRY 2020
- BEATW N/A
- Fundamental
- Price
- THRY $12.07
- BEATW N/A
- Analyst Decision
- THRY Strong Buy
- BEATW
- Analyst Count
- THRY 4
- BEATW 0
- Target Price
- THRY $22.50
- BEATW N/A
- AVG Volume (30 Days)
- THRY 619.2K
- BEATW 4.7K
- Earning Date
- THRY 05-01-2025
- BEATW 03-14-2025
- Dividend Yield
- THRY N/A
- BEATW N/A
- EPS Growth
- THRY N/A
- BEATW N/A
- EPS
- THRY N/A
- BEATW N/A
- Revenue
- THRY $824,156,000.00
- BEATW N/A
- Revenue This Year
- THRY N/A
- BEATW N/A
- Revenue Next Year
- THRY N/A
- BEATW N/A
- P/E Ratio
- THRY N/A
- BEATW N/A
- Revenue Growth
- THRY N/A
- BEATW N/A
- 52 Week Low
- THRY $10.03
- BEATW $0.50
- 52 Week High
- THRY $26.42
- BEATW $0.62
- Technical
- Relative Strength Index (RSI)
- THRY 40.42
- BEATW N/A
- Support Level
- THRY $11.16
- BEATW N/A
- Resistance Level
- THRY $11.93
- BEATW N/A
- Average True Range (ATR)
- THRY 0.91
- BEATW 0.00
- MACD
- THRY 0.12
- BEATW 0.00
- Stochastic Oscillator
- THRY 62.35
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.